Emcure Pharma to Distribute Sanofi's Cardio Products in India

Photo:Representative Image

Sanofi India Limited (SIL) recently obtained approval from its board of directors for an exclusive distribution and promotion agreement with Emcure Pharmaceuticals Limited (Emcure). The agreement is specific to distributing and promoting SIL’s cardiovascular products in India, effective immediately.

Emcure Pharmaceuticals is the exclusive distributor and promoter of the company’s cardiovascular (CV) products, including several well-established brands such as Cardace, Clexane, Targocid, Lasix, and Lasilactone. 

While SIL will continue to own, import, and manufacture these brands across Sanofi’s plants in India and internationally, Emcure will leverage its strengths to engage healthcare professionals and expand the reach of these therapeutic solutions across all areas of India.

Employees of Sanofi India will have the opportunity to work at Emcure. Rodolfo Hrosz, the managing director of Sanofi India Limited, stated, “Sanofi has been committed to improving the lives of patients in India through its range of products. 

Sanofi India has many cardiovascular products that are leaders in their respective categories. With Emcure’s wide presence across India, our partnership will benefit both HCPs (Healthcare Professionals) and patients by creating the opportunity to maximize the reach of our CV products.”

Satish Mehta, the chief executive officer and managing director of Emcure Pharmaceuticals Limited, also expressed his enthusiasm about the partnership and said, “At Emcure Pharmaceuticals, our competitive advantage lies in our established presence in all major therapeutic areas, including cardiology. 

We’re delighted to have the opportunity to partner with Sanofi India, as their range of well-established cardiovascular brands will complement our strong CV portfolio, making it a highly robust offering. Towards this endeavor, Sanofi’s relevant team also has the opportunity to join us.”

Sanofi’s accelerated growth plan - ‘India for India,’ is expected to give fresh impetus to its pharmaceuticals, specialty, consumer healthcare, and vaccines businesses.